• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies.

作者信息

Laham Yousef, Ringelstein-Harlev Shimrit, Kurnik Daniel, Fineman Riva, Yehudai-Ofir Dana, Bonstein Lilach, Setter-Marco Noga, Braun Eyal, Ghersin Itai, Zuckerman Tsila, Beyar-Katz Ofrat

机构信息

Department of Internal Medicine H, Rambam Health Care Campus, Haifa.

Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa.

出版信息

Haematologica. 2025 May 1;110(5):1232-1235. doi: 10.3324/haematol.2024.286714. Epub 2025 Jan 9.

DOI:10.3324/haematol.2024.286714
PMID:39781629
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12050934/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e2c/12050934/5cf24a05f2c5/1101232.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e2c/12050934/27cc4654c81b/1101232.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e2c/12050934/5cf24a05f2c5/1101232.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e2c/12050934/27cc4654c81b/1101232.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e2c/12050934/5cf24a05f2c5/1101232.fig2.jpg

相似文献

1
High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies.对于标准治疗难治的迟发性高级别免疫效应细胞相关血液毒性患者，高剂量静脉注射免疫球蛋白可能是一种有效的治疗选择。
Haematologica. 2025 May 1;110(5):1232-1235. doi: 10.3324/haematol.2024.286714. Epub 2025 Jan 9.
2
Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report.细胞因子释放综合征和免疫效应细胞相关神经毒性综合征患者的嵌合抗原受体T细胞相关毒性管理，随后发生肠穿孔：一例报告
J Med Case Rep. 2025 Jan 20;19(1):27. doi: 10.1186/s13256-024-04905-5.
3
Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma.舒尼替尼在日本肾细胞癌患者中早期血液毒性的特征。
BMC Cancer. 2017 Mar 23;17(1):214. doi: 10.1186/s12885-017-3205-9.
4
Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.阿基仑赛与替雷利珠单抗治疗复发或难治性大B细胞淋巴瘤的系统评价与Meta分析
Transplant Cell Ther. 2024 Jun;30(6):584.e1-584.e13. doi: 10.1016/j.jtct.2024.01.074. Epub 2024 Jan 26.
5
Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of Lu-DOTATATE PRRT.依维莫司或舒尼替尼预处理对 Lu-DOTATATE PRRT 亚急性血液毒性的影响。
Acta Oncol. 2020 Jun;59(6):644-651. doi: 10.1080/0284186X.2020.1723161. Epub 2020 Feb 8.
6
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.利妥昔单抗：用于非霍奇金淋巴瘤和慢性淋巴细胞白血病的综述
Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005.
7
Mechanisms and management of CAR T toxicity.嵌合抗原受体T细胞毒性的机制与管理
Front Oncol. 2024 May 21;14:1396490. doi: 10.3389/fonc.2024.1396490. eCollection 2024.
8
Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity.开发和验证一种自动计算方法，以评估免疫效应细胞相关血液毒性的程度。
Bone Marrow Transplant. 2024 Jul;59(7):910-917. doi: 10.1038/s41409-024-02278-3. Epub 2024 Apr 16.
9
Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia.全血细胞毒性的发展：预测B细胞急性淋巴细胞白血病中CAR T细胞治疗后的血液毒性
Blood. 2025 Mar 13;145(11):1136-1148. doi: 10.1182/blood.2024025910.
10
The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy.早期与晚期使用托珠单抗对免疫效应细胞疗法继发细胞因子释放综合征患者的影响。
J Oncol Pharm Pract. 2023 Jan;29(1):45-51. doi: 10.1177/10781552211052635. Epub 2021 Nov 24.

引用本文的文献

1
Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies.免疫效应细胞相关的血液毒性：机制、临床表现及管理策略。
Haematologica. 2025 Jun 1;110(6):1254-1268. doi: 10.3324/haematol.2024.286027. Epub 2025 Feb 20.

本文引用的文献

1
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management.嵌合抗原受体 T 细胞（CAR T）治疗后与免疫效应细胞相关的血液毒性：从机制到管理。
Lancet Haematol. 2024 Jun;11(6):e459-e470. doi: 10.1016/S2352-3026(24)00077-2. Epub 2024 May 8.
2
An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA.代表欧洲血液与骨髓移植协会（EBMT）和欧洲血液学协会（EHA）开展的关于嵌合抗原受体（CAR）T细胞治疗后免疫效应细胞相关血液毒性（ICAHT）分级、诊断和管理的国际调查。
Hemasphere. 2023 Apr 27;7(5):e889. doi: 10.1097/HS9.0000000000000889. eCollection 2023 May.
3
Intravenous Immunoglobulin: Mechanism of Action in Autoimmune and Inflammatory Conditions.
静脉注射免疫球蛋白：在自身免疫性和炎症性疾病中的作用机制。
J Allergy Clin Immunol Pract. 2023 Jun;11(6):1688-1697. doi: 10.1016/j.jaip.2023.04.002. Epub 2023 Apr 14.
4
Low-dose administration of prednisone has a good effect on the treatment of prolonged hematologic toxicity post-CD19 CAR-T cell therapy.小剂量地塞米松给药对 CD19 CAR-T 细胞治疗后长期血液学毒性的治疗有良好效果。
Front Immunol. 2023 Mar 14;14:1139559. doi: 10.3389/fimmu.2023.1139559. eCollection 2023.
5
Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine.病例报告：利妥昔单抗联合苯达莫司汀后迟发性免疫性中性粒细胞减少症采用大剂量静脉注射免疫球蛋白治疗成功
Front Immunol. 2022 Jan 10;12:798251. doi: 10.3389/fimmu.2021.798251. eCollection 2021.
6
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies.与其他疗法相比，使用商业化嵌合抗原受体T细胞（CAR T细胞）治疗的弥漫性大B细胞淋巴瘤（DLBCL）患者的治疗结果。
Blood Adv. 2020 Oct 13;4(19):4669-4678. doi: 10.1182/bloodadvances.2020002118.
7
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.ASTCT 细胞因子释放综合征和免疫效应细胞相关神经系统毒性的共识分级标准。
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.
8
Intravenous immunoglobulin induces short-term reversal of drug-induced autoimmune neutropenia.静脉注射免疫球蛋白可诱导药物性自身免疫性中性粒细胞减少症的短期逆转。
Transfus Med. 2015 Oct;25(5):347-8. doi: 10.1111/tme.12228. Epub 2015 Jul 20.
9
Intravenous immune globulin in autoimmune and inflammatory diseases.静脉注射免疫球蛋白在自身免疫性和炎性疾病中的应用
N Engl J Med. 2012 Nov 22;367(21):2015-25. doi: 10.1056/NEJMra1009433.
10
A novel tool for high-throughput screening of granulocyte-specific antibodies using the automated flow cytometric granulocyte immunofluorescence test (Flow-GIFT).一种使用自动流式细胞术粒细胞免疫荧光试验（Flow-GIFT）进行粒细胞特异性抗体高通量筛选的新型工具。
ScientificWorldJournal. 2011 Feb 3;11:302-9. doi: 10.1100/tsw.2011.20.